Neuroradiology: Page 203

Medtronic inks distribution deal with Axon

By AuntMinnie.com staff writers

Interventional technology firm Medtronic of Minneapolis has entered into an agreement with Axon Systems, a private developer of neuromonitoring technology used during spinal surgery.

July 25, 2007

NeuroLogica signs Raiders

By AuntMinnie.com staff writers

Portable CT developer NeuroLogica said that the Oakland Raiders of the National Football League (NFL) will be using its CereTom scanner during the 2007 NFL season.

July 25, 2007

Neurognostics adds partnership

By AuntMinnie.com staff writers

Functional MRI (fMRI) developer Neurognostics has signed an agreement with Psychological and Neurobehavioral Sciences in Lakeland, FL.

July 24, 2007

Patient particulars, subtle clues steer cerebrovascular exam decisions

By Eric Barnes

With cerebrovascular imaging, choosing an exam modality such as CT angiography (CTA), MR angiography (MRA), ultrasound, or digital subtraction angiography (DSA) may hinge on a patient's age, sex, medical history -- or when all else fails, a hunch.

July 22, 2007

Philips begins trial of PET/MR CAD software

By AuntMinnie.com staff writers

Phillips Medical Systems and the University Medical Center Hamburg-Eppendorf (UKE) in Germany said they have developed a computer-aided detection (CAD) system designed to assist in the diagnosis of neurodegenerative disease.

June 26, 2007

Studies link Alzheimer's to beta-amyloid and potential for new ligand

By Wayne Forrest

Two studies by Australian researchers are shedding light on Alzheimer's disease. The first looked at the cause of the debilitating condition and the connection between the presence of the toxic brain protein beta-amyloid and Alzheimer's. The other study examined the potential of a new biomarker for disease detection, offering the first results from human studies of the F-18 PET ligand for brain beta-amyloid imaging.

June 25, 2007

Bayer Schering Pharma licenses Avid's imaging agent

By AuntMinnie.com staff writers

Bayer Schering Pharma of Leverkusen, Germany, has exercised its right to license Avid Radiopharmaceuticals' F-18 AV1/ZK molecular imaging agent that targets amyloid plaques in the brain.

June 18, 2007

Neurognostics completes USC fMRI installation

By AuntMinnie.com staff writers

Neurognostics of Milwaukee has installed its functional MRI (fMRI) suite of products and services at University of Southern California in Los Angeles.

June 18, 2007

Report: Equipment malfunction stops cancer treatments

By AuntMinnie.com staff writers

The Associated Press in Paris is reporting that hundreds of brain cancer patients in France, the U.S., and Spain may be contacted about their radiation treatments from malfunctioning machines.

June 14, 2007

First PET/MRI brain images debut at SNM 2007

By Wayne Forrest

Physicians and radiologists may have another hybrid imaging technology to delve deeper into the burgeoning realm of molecular imaging and investigate neurological studies, as well as certain forms of cancer, stroke, and stem cell therapy. Researchers from Germany and the U.S. unveiled the world's first human brain images from a work-in-progress PET/MRI system at the 2007 SNM meeting last week in Washington, DC.

June 14, 2007

HARM makes good on poststroke MR, exposes blood-brain barrier disruption

By Shalmali Pal

When stroke patients undergo standard FLAIR MR imaging, delayed gadolinium enhancement in the cerebral spinal fluid space -- or what researchers at the National Institute of Neurological Disorders and Stroke are calling hyperintense acute reperfusion marker (HARM) -- may indicate early blood-brain barrier disruption, reperfusion injury, hemorrhagic transformation, and poor clinical outcome. HARM also could help broaden the therapeutic window for stroke patients.

June 14, 2007

Diffusion-weighted MRI: The cornerstone of neuroimaging-based stroke studies

By Shalmali Pal

A multitude of new studies published in the journal Stroke examine the increasing validity of MR in stroke imaging. The technique discussed in two papers is the diffusion-perfusion mismatch model with the goal of devising a "simple and practical means" of pinpointing the ischemic penumbra and identifying patients who are more likely to respond to reperfusion therapy. In the third, DWI results are used to create an outcome prediction model.

June 13, 2007

Previous Page

Page 203 of 239

Next Page